BOULDER, CO
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)DYSTROPHIC EPIDERMOLYSIS BULLOSA RESEARCH ASSOCIATION OF AMERICA, founded in 1979, is a community nonprofit that reported $3.2M in total revenue in fiscal year 2024. Revenue surged 21% from the prior year, signaling strong growth momentum. Expenses of $3.6M exceeded revenue, resulting in a 15% operating deficit.
DEBRA IS DEDICATED TO FINDING A CURE FOR EBIDERMOLYSIS BULLOSA " EB" WHICH EFFECTS 1 OUT OF EVERY 50,000 LIVE BIRTHS IN THE UNITED STATES TODAY. EB IS A GENETICALLY BASED DISEASE CHARACTERIZED BY CHRONIC, PAINFULL BLISTERING. THE SKIN AND MUCOUS MEMBRANES ARE SO FRAGILE THAT THE SLIGHTEST TOUCH CAN CAUSE SEVERE BLISTERING INSIDE AND OUTSIDE THE BODY. PRESENT AT BIRTH, EB EFFECTS MEN AND WOMEN OF ALL RACES AND ETHNIC GROUPS, AND SOMETIMES, WHEN THERE IS NO FAMILY HISTORY. IT OCCURS AS THE RESULT OF A SPONTANEOUS GENETIC MUTATION. TODAY, THERE IS NO CURE OR TREATMENT FOR EB, EXCEPT DAILY WOUND CARE AND BANDAGING. GENETIC RESEARCH IS MAKING PROGRESS TOWARDS TREATMENTS AND A CURE.
PUBLIC AND PROFESSIONAL EDUCATION - EDUCATE THE PUBLIC & HEALTH PROFESSIONALS ABOUT DYSTROPHIC EPIDERMOLYSIS BULLOSA "EB"
PATIENT & FAMILY SERVICES - PROVIDE SERVICES FOR THE PEOPLE WITH EB AND THEIR FAMILIES THROUGH NEWSLETTERS, COUNSELING, PEER SUPPORT SERVICES, CONFERENCES AND SEMINARS
ADVOCACY - NETWORK WITH OTHER PROFESSIONAL ORGANIZATIONS AND MEET KEY LEGISLATORS TO INFORM THEM OF EB AND SECURE RESEARCH FUNDS
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $3,150,804 | $2,604,819 | +0.2% |
| Expenses | $3,631,440 | $1,572,705 | +1.3% |
| Net Income | $-480,636 | $1,032,114 | -1.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| BRETT KOPELAN | EXECUTIVE DIRECTOR | 40.0 |
Officer
|
$304,910 | $9,450 | $314,360 |
| J ALEC ALEXANDER | TREASURER | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| RICHARD GALLAGHER | CHAIR EMERITUS | 1.0 |
Director
|
$0 | $0 | $0 |
| ROBERT RYAN Ph D | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JOHN LEE | SECRETARY | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| WILLIAM CORNMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JAMES WETRICH | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| LESLIE RADER | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ANGELA CHRISTIANO PhD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RYAN FULLMER | President | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| ROB RAYL | Vice President | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| Jouni Uitto | Director | 1.0 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $3,150,804 | $3,631,440 | $1,369,762 | $-480,636 |
| 2023 | $2,604,819 | $1,572,705 | $1,940,472 | $1,032,114 |
| 2022 | $3,356,992 | $1,969,058 | $2,090,353 | $1,387,934 |
| 2021 | $1,109,789 | $1,672,683 | $2,216,777 | $-562,894 |
| 2020 | $1,875,849 | $1,367,432 | $2,976,485 | $508,417 |
| 2019 | $1,561,298 | $1,465,695 | $2,407,080 | $95,603 |
Compare DYSTROPHIC EPIDERMOLYSIS BULLOSA RESEARCH ASSOCIATION OF AMERICA with other nonprofits in Colorado and across the country.